CORPORATE VISION / June 2017 97 , BioVision, Inc, is a privately held life science company headquartered in the beautiful San Francisco Bay area. CEO and founder, Dr Gordon Yan, was recently awarded the prestigious title of CEO of the Year, after whichwe profiled the firm’s work. The Science of Life Dr Gordon Yan, Ph.D., is the Chief Executive Officer and Founder at BioVision, Inc. since January 1996. Dr Yan holds a Ph.D. in Molecular Cellular Biology and M.S. in Molecular Biology from Clarkson University in the year 1992 and 1990 respectively and a Bachelor of Science in Biochemistry from Jilin University in the year 1984. BioVision, Inc., is a privately held life science company headquartered in the beautiful San Francisco Bay Area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying apoptosis, metabolism, cell proliferation, cellular stress, cell damage and repair as well as diabetes, obesity and metabolic syndrome, stem cell biology, gene regulation and signal transduction. BioVision’s products are currently being sold in more than 60 countries worldwide. BioVision aims to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate drug discovery in disease-related areas like cancer, diabetes, obesity, Alzheimer’s disease and so on. The firm would achieve these goals through a well-defined core strategy and a company culture that fosters integrity, openness, and collaboration, and rewards customer focus, innovation and ownership. Two examples of the firm’s work are listed below, but many more can be at: www. biovision.com . Cardiovascular diseases (CVD) In terms of the cardiovascular diseases (CVD), these are the leading cause of morbidity and mortality worldwide. The basis of CVD encompasses damages to the heart and blood vessels that can eventually obstruct blood flow. Diseases under this broad umbrella include coronary artery diseases (e.g. myocardial infarctions or heart attack, angina etc.), arrhythmia, stroke, congenital heart defects and renal/ vascular disorders. Multiple risk factors for CVD include age, diet, lifestyle changes, genetic predispositions and family history of hypertension, diabetes and/ or obesity. BioVision offers a comprehensive portfolio of products comprising of assay kits, recombinant proteins, antibodies and biochemicals to facilitate research in cardiovascular biology, drug development and biomarker discovery. • Cardiovascular research categories; • Angiogenesis; • Arrhythmia & cardiac arrest; • Atherosclerosis; • Cytokines, growth factors, hormones; • Diabetes and obesity; • Hypertension; • Ischemia reperfusion injury; • Myocardial infarction and; • Renal injury/kidney disease. Diabetes, Obesity & Metabolic Syndrome Diabetes is one of the most challenging health problems in the 21st century and one of the most common non- communicable diseases globally. It is the 4th or 5th leading cause of death in most high- income countries, with ~366 million diabetics in 2011 and an estimated 552 million in 2030. About 11% of total adult healthcare expenditure in the US and 8-18% in the EU is diabetes related. Asia is emerging as the epicentre of the diabetes epidemic. India and China have the greatest numbers of people with diabetes, and by 2025, they could each have 20 million affected individuals. The global diabetes drug and devices market is estimated to be a whopping 72.4 billion by 2018. Understandably the number of studies on diabetes over the last 20 years has also been extraordinary. On the other hand, obesity has also become a world-wide epidemic. For the first time in human history, the number of overweight people rivals the number of underweight people. Globally, there are > 1 billion overweight adults with about 300 million clinically obese. Of the 22 industrialised countries, the U.S. has the highest obesity statistics. About 2/3rd of Americans over age 20 are overweight. About 1/3rd of Americans over age 20 are obese. According to new statistics released by the CDC, the number of obese American adults (~34%) now outnumber those who are overweight (~33%). It is estimated that if current obesity trends continue, by the year 2030, 86.3% of adults will be overweight or obese and 51.1% will be obese and by 2048 all adults will be overweight or obese. Obesity-related annual healthcare costs in the US equals about 240 billion. Obesity is also responsible for 2–8% of healthcare costs and 10–13% of deaths in different parts of EU. In the South-East Asia Region, about 300,000 people die of obesity every year. Company: BioVision, Inc. Name: Gordon Yan, Ph.D. Email:
[email protected] Web Address: www.biovision.com Address: 155 S. Milpitas BLVD Milpitas, CA 95035 Telephone: +1 408 493 1831 1703CV33